NEW
Stock Screener with Intrinsic Value
Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$238.0(1.1%)
Market Cap$30.1B
LTM EPS
($2.6)
-25.8% YOY growth
NTM EPS
($2.6)
-2.0% YOY growth
Current P/E
(90.7x) LTM
(106.8x) NTM
52w high P/E
(42.0x) LTM
(31.2x) NTM
52w low P/E
(498.7x) LTM
(115.4x) NTM
10Y avg P/E
(36.2x) LTM
(22.5x) NTM
ALNY Peter Lynch Chart
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Explore more intrinsic value tools hub for ALNY
Earnings growth model
Peter Lynch Fair Value
Earnings Power Value
Discount rate
Ben Graham Fair Value
Reverse DCF
Relative Value
Intrinsic Value
DCF value calculator
Margin of safety
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Alnylam Pharmaceuticals, Inc. earnings per share (EPS)?
Alnylam Pharmaceuticals, Inc. earnings per share (EPS) for the twelve months ending Jan 10, 2025 was ($2.6), a (25.8%) increase year-over-year.
What is Alnylam Pharmaceuticals, Inc. Price to Earnings (P/E) ratio?
As of Jan 10, 2025, Alnylam Pharmaceuticals, Inc.'s P/E ratio is (90.7x). This is calculated by dividing the current share price of $238.0 by the Earnings per Share (EPS) for the trailing twelve months, which is ($2.6). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
Is Alnylam Pharmaceuticals, Inc. overvalued or undervalued?
Alnylam Pharmaceuticals, Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $84.9, compared to a market price of around $238.0. This suggests a potential overvaluation of 64.3%.